Fig. 1: TCGA analysis shows expression profile, clinicopathological associations, and prognostic and diagnostic value of MRPL17 in NSCLC. | Cell Death & Disease

Fig. 1: TCGA analysis shows expression profile, clinicopathological associations, and prognostic and diagnostic value of MRPL17 in NSCLC.

From: MRPL17 is a critical regulator of mitochondrial function and a novel therapeutic target in non-small cell lung cancer

Fig. 1

Transcriptomic analysis of TCGA (The Cancer Genome Atlas) datasets conducted to evaluate the expression levels of MRPL17 in LUAD and LUSC tumor tissues compared to normal lung tissues (A). Direct comparison performed on paired tissue samples to assess MRPL17 expression within LUAD (B) or LUSC (C) tumor tissues relative to adjacent normal lung tissues. The analyses were performed to investigate the potential difference in MRPL17 expression based on the smoking status (D), pathological T stages (T1&T2 vs. T3&T4) (E), the presence or absence of lymph node metastasis (N0 vs. N1, N2&N3) (F), distant metastasis status (M0 vs. M1) (G), or across different pathological stages (Stage I vs. Stage II and Stage III&IV) (H) of the NSCLC patients. Kaplan-Meier survival analysis conducted to evaluate the correlation between MRPL17 expression and overall survival (OS) (I), disease-specific survival (DSS) (J) or progression-free interval (PFI) (K) in NSCLC patients (combining LUSD and LUAD). Receiver operating characteristic (ROC) curve analysis performed to evaluate the diagnostic utility of MRPL17 expression in differentiating between NSCLC and normal lung tissues (L). Asterisks denote statistical significance: *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page